Icosavax, Inc.
ICVXDelisted- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001786255
Icosavax, Inc. was delisted in 2024; its insiders filed their last Form 4 on Feb 20, 2024; 93 institutions reported holding it in 13F filings for Q4 2023, worth $664.5M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 93
- Q4 2023, +29 vs. previous quarter
- 13F value
- $663.0M
- Reported value at the end of Q4 2023
- Superinvestors holding
- 0
- At the end of Q4 2023
Superinvestors holding ICVX, Q4 2023
No superinvestor reported holding ICVX at the end of Q4 2023.
Latest insider trades
Open-market purchases and sales by Icosavax, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 2, 2024 (view filing) | Feb 1 | 1 day | Simpson Adam K.Chief Executive Officer | SSale | −15.0K | $15.29 | −$229.3K | −4.0%358.7K after | 10b5-1 |
| Jan 5, 2024 (view filing) | Jan 4, 2023 | 366 daysLate | Kanesa-thasan NiranjanChief Medical Officer | SSale | −106.4K | $15.70 | −$1.67M | −32.2%224.0K after | |
| Jan 4, 2024 (view filing) | Jan 2 | 2 days | Simpson Adam K.Chief Executive Officer | SSale | −15.0K | $15.67 | −$235.1K | −5.4%260.6K after | 10b5-1 |
| Dec 22, 2023 (view filing) | Dec 20-21 | 2 days | Simpson Adam K.Chief Executive Officer | SSale | −152.2K | $15.45 | −$2.35M | −36.9%260.6K after | 3 lots10b5-1 |
| Dec 22, 2023 (view filing) | Dec 20 | 2 days | Russo Thomas JosephChief Financial Officer | SSale | −15.2K | $15.46 | −$234.8K | −28.5%38.0K after | 2 lots |
| Dec 22, 2023 (view filing) | Dec 20 | 2 days | Kanesa-thasan NiranjanChief Medical Officer | SSale | −11.9K | $15.46 | −$183.7K | −5.0%224.0K after | |
| Dec 22, 2023 (view filing) | Dec 20 | 2 days | Cearley CassiaChief Business Officer | SSale | −7.93K | $15.46 | −$122.7K | −5.7%130.7K after | |
| Dec 15, 2023 (view filing) | Dec 13 | 2 days | Cearley CassiaChief Business Officer | SSale | −8.76K | $16.01 | −$140.2K | −6.3%131.2K after | 10b5-1 |
| Aug 1, 2023 (view filing) | Jul 31 | 1 day | Kanesa-thasan NiranjanChief Medical Officer | SSale | −3.32K | $8.86 | −$29.4K | −1.4%235.9K after | 10b5-1 |
| Aug 1, 2023 (view filing) | Jul 31 | 1 day | Simpson Adam K.Chief Executive Officer | SSale | −11.8K | $8.86 | −$104.4K | −4.6%243.9K after | 10b5-1 |
Top 10 13F holders, Q4 2023
The largest institutional positions in Icosavax, Inc. at the end of Q4 2023; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 5,963,565 | $94.0M | 1.47% | 00.0% | Unchanged |
| T. Rowe Price Investment Management, Inc. | 3,926,407 | $61.9M | 0.04% | −909,244−18.8% | Reduced |
| TCG Crossover Management, LLC | 3,703,704 | $58.4M | 6.47% | 00.0% | Unchanged |
| Qiming U.S. Ventures Management, LLC | 3,510,228 | $55.3M | 50.66% | 00.0% | Unchanged |
| Pentwater Capital Management LP | 3,000,000 | $47.3M | 0.89% | +3,000,000 | New |
| BlackRock Inc. | 2,581,530 | $40.7M | 0.00% | +585,250+29.3% | Added |
| FMR LLC | 2,240,524 | $35.3M | 0.00% | −3,213,424−58.9% | Reduced |
| Vanguard Group Inc | 1,830,058 | $28.8M | 0.00% | −68,229−3.6% | Reduced |
| Vivo Capital, LLC | 1,704,568 | $26.9M | 2.20% | 00.0% | Unchanged |
| Alpine Associates Management Inc. | 1,456,700 | $23.0M | 1.18% | +1,456,700 | New |